Merck & Co in $2.7bn cancer research acquisition

12-12-2019

Rory O'Neill

Merck & Co in $2.7bn cancer research acquisition

Atmosphere1 / Shutterstock.com

Merck & Co has announced its acquisition of biotechnology company ArQule in a $2.7 billion deal.


Merck & Co, cancer research, ArQule, Sanofi, Synthorx, biotechnology

More on this story

Sanofi buys Synthorx for $2.5 billion
10-12-2019

LSIPR